Phillip M. Mackie

Phillip M. Mackie

Auto-generated profile, based on publicly available information

Phillip M. Mackie

Department of Neuroscience, University of Florida College of Medicine, Gainesville, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
PMPhillip M. Mackie
Phillip M. Mackie
AGAdithya Gopinath
Adithya Gopinath
DMDominic M. Montas
Dominic M. Montas
ANAlyssa Nielsen
Alyssa Nielsen
ASAidan Smith
Aidan Smith
Habibeh KhoshboueiHabibeh Khoshbouei
Habibeh Khoshbouei
Monocyte-derived macrophages (MDMs) are key players in tissue homeostasis and diseases regulated by a variety of signaling molecules. Recent literature has highlighted the ability for biogenic amines to regulate macrophage functions, but the mechanisms governing biogenic amine signaling in and around immune cells remain nebulous. In the CNS, biogenic amine transporters are regarded as the master regulators of neurotransmitter signaling. While we and others have shown that macrophages express these transporters, relatively little is known of their function in these cells. To address these knowledge gaps, we investigated the function of norepinephrine transporter (NET) and dopamine transporter (DAT) on human MDMs. We found that both NET and DAT are present and can uptake substrate from the extracellular space at baseline. Not only was DAT expressed in cultured MDMs, but it was also detected in a subset of intestinal macrophages in situ. Surprisingly, we discovered a NET-independent, DAT-mediated immunomodulatory mechanism in response to LPS. LPS induced reverse transport of dopamine through DAT, engaging an autocrine/paracrine signaling loop that regulated the macrophage response. Removing this signaling loop enhanced the proinflammatory response to LPS. Our data introduce a potential role for DAT in the regulation of innate immunity.

10 January 2023 in Cells
Verified
Journal Article
Open access
PDF file
AGAdithya Gopinath
Adithya Gopinath
PMPhillip M. Mackie
Phillip M. Mackie
LPLeah T. Phan
Leah T. Phan
RMRosa Mirabel
Rosa Mirabel
ASAidan R. Smith
Aidan R. Smith
Habibeh KhoshboueiHabibeh Khoshbouei
Habibeh Khoshbouei
The dopamine transporter (DAT) regulates the dimension and duration of dopamine transmission. DAT expression, its trafficking, protein–protein interactions, and its activity are conventionally studied in the CNS and within the context of neurological diseases such as Parkinson’s Diseases and neuropsychiatric diseases such as drug addiction, attention deficit hyperactivity and autism. However, DAT is also expressed at the plasma membrane of peripheral immune cells such as monocytes, macrophages, T-cells, and B-cells. DAT activity via an autocrine/paracrine signaling loop regulates macrophage responses to immune stimulation. In a recent study, we identified an immunosuppressive function for DAT, where blockade of DAT activity enhanced LPS-mediated production of IL-6, TNF-α, and mitochondrial superoxide levels, demonstrating that DAT activity regulates macrophage immune responses. In the current study, we tested the hypothesis that in the DAT knockout mice, innate and adaptive immunity are perturbed. We found that genetic deletion of DAT (DAT−/−) results in an exaggerated baseline inflammatory phenotype in peripheral circulating myeloid cells. In peritoneal macrophages obtained from DAT−/− mice, we identified increased MHC-II expression and exaggerated phagocytic response to LPS-induced immune stimulation, suppressed T-cell populations at baseline and following systemic endotoxemia and exaggerated memory B cell expansion. In DAT−/− mice, norepinephrine and dopamine levels are increased in spleen and thymus, but not in circulating serum. These findings in conjunction with spleen hypoplasia, increased splenic myeloid cells, and elevated MHC-II expression, in DAT−/− mice further support a critical role for DAT activity in peripheral immunity. While the current study is only focused on identifying the role of DAT in peripheral immunity, our data point to a much broader implication of DAT activity than previously thought. This study is dedicated to the memory of Dr. Marc Caron who has left an indelible mark in the dopamine transporter field.

2 October 2024 in BMJ Open Quality
Verified
Journal Article
Open access
PDF file
RKRené Marcella Kronlage
René Marcella Kronlage
ASAmy S Stanley
Amy S Stanley
MRMiranda J Reid
Miranda J Reid
WSWilliam Hudson Shaw
William Hudson Shaw
CHCara E House
Cara E House
CHCarolyn K Holland
Carolyn K Holland
Background The University of Florida (UF) Equal Access Clinic Network (EACN) is the largest student-run free healthcare clinic network in Florida. The UF EACN serves those who are underinsured or uninsured in Alachua County and its surrounding area. Nationally, average total clinic time per medical visit has been established to be 84 min. Problem Before this project, average patient cycle time at the UF EACN was 125.3 min, and there was no established quality improvement (QI) team to implement changes to address inefficiencies. Methods This was a prospective QI study that recorded patient cycle times for patients who received healthcare at any of the four primary care free clinics across the UF EACN from 5 July 2022 to 6 April 2023. Interventions Eighteen Plan–Do–Study–Act cycles were tailored to each of the four primary care clinic’s needs with a focus on reducing patient cycle time by addressing the following identified problems: prolonged intake process, translation services, limited numbers of volunteers, and other inefficiencies and bottlenecks in workflow. Results The median patient cycle time at the EACN shifted from 125.3 min to 112.7 min over a nine month period. This drop of 12.6 min meant patients saw a 10.1% reduction in patient cycle time across the EACN. Conclusion Underserved patients at EACN are experiencing increased value by having shorter patient cycle times.

28 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
PMPhillip M Mackie
Phillip M Mackie
JKJoanne Koshy
Joanne Koshy
MBMauli Bhogade
Mauli Bhogade
THTristan Hammoor
Tristan Hammoor
WHWilliam Hachmeister
William Hachmeister
Habibeh KhoshboueiHabibeh Khoshbouei
Habibeh Khoshbouei
Summary: Deposition of misfolded α-synuclein (αsyn) in the enteric nervous system (ENS) is found in multiple neurodegenerative diseases. It is hypothesized that ENS synucleinopathy contributes to both the pathogenesis and non-motor morbidity in Parkinson’s Disease (PD), but the cellular and molecular mechanisms that shape enteric histopathology and dysfunction are poorly understood. Here, we demonstrate that ENS-resident macrophages, which play a critical role in maintaining ENS homeostasis, initially respond to enteric neuronal αsyn pathology by upregulating machinery for complement-mediated engulfment. Pharmacologic depletion of ENS-macrophages or genetic deletion of C1q enhanced enteric neuropathology. Conversely, C1q deletion ameliorated gut dysfunction, indicating that complement partially mediates αsyn-induced gut dysfunction. Internalization of αsyn led to increased endo-lysosomal stress that resulted in macrophage exhaustion and temporally correlated with the progression of ENS pathology. These novel findings highlight the importance of enteric neuron-macrophage interactions in removing toxic protein aggregates that putatively shape the earliest stages of PD in the periphery.

20 January 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
PMPhillip M. Mackie
Phillip M. Mackie
JKJoanne M. Koshy
Joanne M. Koshy
MBMauli H. Bhogade
Mauli H. Bhogade
THTristan Hammoor
Tristan Hammoor
WHWilliam Hachmeister
William Hachmeister
Habibeh KhoshboueiHabibeh Khoshbouei
Habibeh Khoshbouei
Deposition of misfolded α-synuclein (αsyn) in the enteric nervous system (ENS) is found in multiple neurodegenerative diseases. It is hypothesized that ENS synucleinopathy contributes to both the pathogenesis and non-motor morbidity in Parkinson’s Disease (PD), but the cellular and molecular mechanisms that shape enteric histopathology and dysfunction are poorly understood. Here, we employ a fibrillar injection model of enteric synucleinopathy in male mice and demonstrate that ENS-resident macrophages, which play a critical role in maintaining ENS homeostasis, initially respond to enteric neuronal αsyn pathology by upregulating machinery for complement-mediated engulfment. Pharmacologic depletion of ENS-macrophages or genetic deletion of C1q enhanced enteric neuropathology. Conversely, C1q deletion ameliorated gut dysfunction, indicating that complement partially mediates αsyn-induced gut dysfunction. However, this C1q-dependent clearance mechanism diminished over time and its failure temporally correlated with the further increase in ENS pathology. These findings highlight the importance of enteric neuron-macrophage interactions in removing toxic protein aggregates that putatively shape the gastrointestinal manifestations of PD.